381 related articles for article (PubMed ID: 24307692)
1. Indolcarboxamide is a preclinical candidate for treating multidrug-resistant tuberculosis.
Rao SP; Lakshminarayana SB; Kondreddi RR; Herve M; Camacho LR; Bifani P; Kalapala SK; Jiricek J; Ma NL; Tan BH; Ng SH; Nanjundappa M; Ravindran S; Seah PG; Thayalan P; Lim SH; Lee BH; Goh A; Barnes WS; Chen Z; Gagaring K; Chatterjee AK; Pethe K; Kuhen K; Walker J; Feng G; Babu S; Zhang L; Blasco F; Beer D; Weaver M; Dartois V; Glynne R; Dick T; Smith PW; Diagana TT; Manjunatha UH
Sci Transl Med; 2013 Dec; 5(214):214ra168. PubMed ID: 24307692
[TBL] [Abstract][Full Text] [Related]
2. Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection.
Stec J; Onajole OK; Lun S; Guo H; Merenbloom B; Vistoli G; Bishai WR; Kozikowski AP
J Med Chem; 2016 Jul; 59(13):6232-47. PubMed ID: 27275668
[TBL] [Abstract][Full Text] [Related]
3. Direct inhibitors of InhA are active against Mycobacterium tuberculosis.
Manjunatha UH; S Rao SP; Kondreddi RR; Noble CG; Camacho LR; Tan BH; Ng SH; Ng PS; Ma NL; Lakshminarayana SB; Herve M; Barnes SW; Yu W; Kuhen K; Blasco F; Beer D; Walker JR; Tonge PJ; Glynne R; Smith PW; Diagana TT
Sci Transl Med; 2015 Jan; 7(269):269ra3. PubMed ID: 25568071
[TBL] [Abstract][Full Text] [Related]
4. Inoculum-dependent bactericidal activity of a
Berube B; Deshpande A; Bhagwat A; Parish T
Microbiology (Reading); 2023 Jun; 169(6):. PubMed ID: 37334886
[TBL] [Abstract][Full Text] [Related]
5. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Potential of the Mycobacterium tuberculosis Mycolic Acid Transporter, MmpL3.
Li W; Obregón-Henao A; Wallach JB; North EJ; Lee RE; Gonzalez-Juarrero M; Schnappinger D; Jackson M
Antimicrob Agents Chemother; 2016 Sep; 60(9):5198-207. PubMed ID: 27297488
[TBL] [Abstract][Full Text] [Related]
7. Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in vivo.
Shirude PS; Shandil R; Sadler C; Naik M; Hosagrahara V; Hameed S; Shinde V; Bathula C; Humnabadkar V; Kumar N; Reddy J; Panduga V; Sharma S; Ambady A; Hegde N; Whiteaker J; McLaughlin RE; Gardner H; Madhavapeddi P; Ramachandran V; Kaur P; Narayan A; Guptha S; Awasthy D; Narayan C; Mahadevaswamy J; Vishwas KG; Ahuja V; Srivastava A; Prabhakar KR; Bharath S; Kale R; Ramaiah M; Choudhury NR; Sambandamurthy VK; Solapure S; Iyer PS; Narayanan S; Chatterji M
J Med Chem; 2013 Dec; 56(23):9701-8. PubMed ID: 24215368
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo activities of a new lead compound I2906 against Mycobacterium tuberculosis.
Lu J; Yue J; Wu J; Luo R; Hu Z; Li J; Bai Y; Tang Z; Xian Q; Zhang X; Wang H
Pharmacology; 2010; 85(6):365-71. PubMed ID: 20530976
[TBL] [Abstract][Full Text] [Related]
9. A piperidinol-containing molecule is active against
Dupont C; Chen Y; Xu Z; Roquet-Banères F; Blaise M; Witt AK; Dubar F; Biot C; Guérardel Y; Maurer FP; Chng SS; Kremer L
J Biol Chem; 2019 Nov; 294(46):17512-17523. PubMed ID: 31562241
[No Abstract] [Full Text] [Related]
10. Advancing the Therapeutic Potential of Indoleamides for Tuberculosis.
Lun S; Tasneen R; Chaira T; Stec J; Onajole OK; Yang TJ; Cooper CB; Mdluli K; Converse PJ; Nuermberger EL; Raj VS; Kozikowski A; Bishai WR
Antimicrob Agents Chemother; 2019 Jul; 63(7):. PubMed ID: 31010860
[TBL] [Abstract][Full Text] [Related]
11. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
12. Structural Basis for the Inhibition of Mycobacterial MmpL3 by NITD-349 and SPIRO.
Yang X; Hu T; Yang X; Xu W; Yang H; Guddat LW; Zhang B; Rao Z
J Mol Biol; 2020 Jul; 432(16):4426-4434. PubMed ID: 32512002
[TBL] [Abstract][Full Text] [Related]
13. Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Hameed P S; Patil V; Solapure S; Sharma U; Madhavapeddi P; Raichurkar A; Chinnapattu M; Manjrekar P; Shanbhag G; Puttur J; Shinde V; Menasinakai S; Rudrapatana S; Achar V; Awasthy D; Nandishaiah R; Humnabadkar V; Ghosh A; Narayan C; Ramya VK; Kaur P; Sharma S; Werngren J; Hoffner S; Panduga V; Kumar CN; Reddy J; Kumar K N M; Ganguly S; Bharath S; Bheemarao U; Mukherjee K; Arora U; Gaonkar S; Coulson M; Waterson D; Sambandamurthy VK; de Sousa SM
J Med Chem; 2014 Jun; 57(11):4889-905. PubMed ID: 24809953
[TBL] [Abstract][Full Text] [Related]
14. Structure activity relationships of 4-hydroxy-2-pyridones: A novel class of antituberculosis agents.
Ng PS; Manjunatha UH; Rao SP; Camacho LR; Ma NL; Herve M; Noble CG; Goh A; Peukert S; Diagana TT; Smith PW; Kondreddi RR
Eur J Med Chem; 2015 Dec; 106():144-56. PubMed ID: 26544629
[TBL] [Abstract][Full Text] [Related]
15. Lipid transport in Mycobacterium tuberculosis and its implications in virulence and drug development.
Bailo R; Bhatt A; Aínsa JA
Biochem Pharmacol; 2015 Aug; 96(3):159-67. PubMed ID: 25986884
[TBL] [Abstract][Full Text] [Related]
16. Antimycobacterial activity of Citrullus colocynthis (L.) Schrad. against drug sensitive and drug resistant Mycobacterium tuberculosis and MOTT clinical isolates.
Mehta A; Srivastva G; Kachhwaha S; Sharma M; Kothari SL
J Ethnopharmacol; 2013 Aug; 149(1):195-200. PubMed ID: 23816500
[TBL] [Abstract][Full Text] [Related]
17. Microarray analysis of efflux pump genes in multidrug-resistant Mycobacterium tuberculosis during stress induced by common anti-tuberculous drugs.
Gupta AK; Katoch VM; Chauhan DS; Sharma R; Singh M; Venkatesan K; Sharma VD
Microb Drug Resist; 2010 Mar; 16(1):21-8. PubMed ID: 20001742
[TBL] [Abstract][Full Text] [Related]
18. Lipiarmycin targets RNA polymerase and has good activity against multidrug-resistant strains of Mycobacterium tuberculosis.
Kurabachew M; Lu SH; Krastel P; Schmitt EK; Suresh BL; Goh A; Knox JE; Ma NL; Jiricek J; Beer D; Cynamon M; Petersen F; Dartois V; Keller T; Dick T; Sambandamurthy VK
J Antimicrob Chemother; 2008 Oct; 62(4):713-9. PubMed ID: 18587134
[TBL] [Abstract][Full Text] [Related]
19. The "source" of drug-resistant TB outbreaks.
van Helden PD; Victor T; Warren RM
Science; 2006 Oct; 314(5798):419-20. PubMed ID: 17053131
[No Abstract] [Full Text] [Related]
20. Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis.
Zhang D; Lu Y; Liu K; Liu B; Wang J; Zhang G; Zhang H; Liu Y; Wang B; Zheng M; Fu L; Hou Y; Gong N; Lv Y; Li C; Cooper CB; Upton AM; Yin D; Ma Z; Huang H
J Med Chem; 2012 Oct; 55(19):8409-17. PubMed ID: 22931472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
